Drugs / BB-12 with LGG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03514784 Comparator | May 2016 → Jul 2025 | autism spectrum disorder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB-12 with LGG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03514784 ↗ |
| Modality | Other / unclassified | “BB-12 with LGG (Multistrain probiotic: higher dose): 10 billion CFUs” NCT03514784 ↗ |